Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OncorMed Inc.

Division of Ore Pharmaceuticals Inc.

Latest From OncorMed Inc.

As Big DX Companies Consolidate, What Are Smaller Companies To Do?

If large diagnostics companies are consolidating at a record pace these days, smaller companies are also struggling for ways to cope with the brutalities of the current market. Some are cutting back on projects or looking to eliminate altogether their involvement in diagnostics. Others are forging relations with other small companies, something they haven't done much of in the past.
Medical Device Business Strategies

Venturing into the Brave New World of Diagnostics Start-Ups

Few diagnostics start-ups are {bona fide} business successes, and that has put a damper on venture capital interest in the field. But this hasn't stopped start-ups trying to meet needs in cancer diagnostics, sample preparation and point-of-care.
BioPharmaceutical Medical Device

Grading Diagnostics Start-Ups

While diagnostics start-ups have delivered good returns to private investors, they've performed miserably for the public, with a few significant exceptions. In this statistical review, we segment the industry, showing the trends that have won with investors (automation, drug-focused diagnostics) and those that have lost big (point-of-care testing).
Medical Device Leadership

Dx Start-Ups: Separating the Wheat From the Chaff

The diagnostics industry has been a tarpit for start-ups. Entrepreneurs rarely overcome the field's serious and often unseen challenges, but a handful are thriving thanks to their realistic assessments of just how complex the industry is and their ability to adapt when products hit brick walls. Accessible market niches are a key to success, so is exploiting drug firms--as customers, marketing channels, or as sources of differentiating technology.
Medical Device Strategy
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ore Pharmaceuticals Inc.
  • Senior Management
  • Timothy J Triche, MD, PhD, Chmn. & CEO
    Lee R Johnston, Jr., VP, CFO
    Douglas Dolginow, MD, Pres. & COO
  • Contact Info
  • OncorMed Inc.
    Phone: (301) 208-1888
    205 Perry Pkwy.
    Gaithersburg, MD 20877